Story: Lixa
Episode: 2
Presenter: Brad Hill
Air Date: 14th April 2024

A mission to resolve a global rise in antibiotic resistance.

• Bacteria are increasingly becoming resistant to antibiotics, posing a threat to humanity. The World Health Organization (WHO) warns of a post-antibiotic era where simple infections could become untreatable, resulting in millions of deaths by 2050 due to antimicrobial resistance (AMR).
• Lixa, is tackling antibiotic resistance differently. Rather than developing new antibiotics, they target bacterial biofilms, which are protective communities making bacteria highly resistant to treatment.
• Lixa's antibiofilm technology, effectively breaks down biofilms, making bacteria susceptible to conventional antibiotics again. Their lead ingredient, NeoX-101, is scalable, cost-effective, and can be easily integrated into existing treatment protocols.
• Lixa is preparing for clinical trials focused on treating recalcitrant infections in patients with conditions like bronchiectasis or cystic fibrosis. Success in these trials could offer a new solution to combat AMR worldwide.
• Bacterial biofilms pose problems beyond human health, affecting various industries. Lixa's technology has potential applications in livestock management, crop protection, water systems, and industrial settings, offering solutions to broad bacterial challenges.
• Lixa envisions itself as a pioneering pharmaceutical company based in WA, aiming to tackle global microbial challenges, save healthcare costs, and create high-value jobs. Supported by various institutions, Lixa seeks partnerships to accelerate development and commercialization.

For more information, head to:
www.lixa.life